Current status of bortezomib in the treatment of multiple myeloma

被引：8

作者：

Cavo M. ^{[1
]}

机构：

[1] Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, 40138, Bologna

来源：

Current Hematologic Malignancy Reports | 2007年 / 2卷 / 2期

关键词：

Multiple Myeloma; Thalidomide; Bortezomib; Myeloma Cell; Lenalidomide;

D O I：

10.1007/s11899-007-0018-y

中图分类号：

学科分类号：

摘要：

Bortezomib (formerly PS-341) has been the first proteasome inhibitor to enter clinical trials in cancer patients. Preclinical studies showing that this novel agent directly inhibits the proliferation of myeloma cells, induces their apoptosis, and abrogates paracrine tumor growth through alteration of interactions of myeloma and stromal cells and through nuclear factor κB-dependent cytokine secretion prompted the design of large phase II and III studies of bortezomib in patients with advanced relapsed and/or refractory multiple myeloma. Favorable results of these studies led to accelerated approval for use of bortezomib in patients with multiple myeloma who have progressed after at least their second therapy and, more recently, to expanded approval for second-line use in patients in whom one prior therapy has failed. Combination studies of bortezomib with various agents, including dexamethasone, DNA-damaging drugs (such as melphalan, cyclophosphamide, and doxorubicin), thalidomide, and lenalidomide, are currently ongoing in patients with both relapsed/refractory and newly diagnosed disease. Bortezomib may be the backbone" for the development of more effective treatment strategies to improve patient outcome in multiple myeloma. Copyright © 2007 by Current Medicine Group LLC."

引用

页码：128 / 137

页数：9

共 46 条

[1]

Ciechanover A., Orian A., Schwartz A.L., Ubiquitin-mediated proteolysis: Biological regulation via destruction, Bioessays, 22, pp. 442-451, (2000)

[2]

Zwickl P., Voges D., Baumeister W., The proteasome: A macromolecular assembly designed for controlled proteolysis [review], Philos Trans R Soc Lond B Biol Sci, 354, pp. 1501-1511, (1999)

[3]

Kisselev A.F., Goldberg A.L., Proteasome inhibitors: From research tools to drug candidates, Chem Biol, 8, pp. 739-758, (2001)

[4]

Voorhees P.M., Dees E.C., O'Neil B., Orlowski R.Z., The proteasome as a target for cancer therapy, Clin Cancer Res, 9, pp. 6316-6325, (2003)

[5]

Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T., The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B, Cell, 78, pp. 773-785, (1994)

[6]

Adams J., Palombella V.J., Sausville E.A., Et al., Proteasome inhibitors: A novel class of potent and effective antitumor agents, Cancer Res, 59, pp. 2615-2622, (1999)

[7]

Cavo M., Proteasome inhibitor bortezomib for the treatment of multiple myeloma, Leukemia, 20, pp. 1341-1352, (2006)

[8]

Hideshima T., Richardson P., Chauhan D., Et al., The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells, Cancer Res, 61, pp. 3071-3076, (2001)

[9]

Mitsiades C.S., Richardson P.G., Poulaki V., Et al., The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications, Blood, 101, pp. 2377-2380, (2003)

[10]

Ma M.H., Yang H.H., Parker K., Et al., The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents, Clin Cancer Res, 9, pp. 1136-1144, (2003)

← 1 2 3 4 5 →